Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Current Design of New Psychoactive Substances (Part 2)

Author(s): Francesco Paolo Busardò and Simona Zaami

Volume 28, Issue 32, 2022

Published on: 27 September, 2022

Page: [2601 - 2602] Pages: 2

DOI: 10.2174/138161282832220927164426

conference banner
Next »
[1]
Busardò FP, Zaami S. Current design of new psychoactive substances. Curr Pharm Des 2022; 28(15): 1211-2.
[2]
Varì MR, Ricci G, Cavallo M, Pichini S, Sirignano A, Graziano S. Ketamine: From Prescription anaesthetic to new psychoactive substance. Curr Pharm Des 2022; 28(15): 1213-20.
[3]
Zaami S, Graziano S, Tittarelli R, Beck R, Marinelli E. BDZs, Designer BDZs and Z-drugs: Pharmacology and misuse insights. Curr Pharm Des 2022; 28(15): 1221-9.
[4]
Gish A, Dumestre-Toulet V, Richeval C, et al. Trends in the pharmaceutical design of new psychoactive substances detected in oral fluid of drivers around a music festival in south-west france: Comparison 2019/2017. Curr Pharm Des 2022; 28(15): 1245-9.
[5]
Sarah MR, Wille SMR, Desharnais B, et al. Liquid chromatography high-resolution mass spectrometry in forensic toxicology: What are the specifics of method development, validation and quality assurance for comprehensive screening approaches? Curr Pharm Des 2022; 28(15): 1230-44.
[6]
Zaami S, Busardò FP, Pichini S, Pacifici R, Marinelli E. The value of toxicological and forensic analyses in the global challenge to health risks caused by new psychoactive substances. Eur Rev Med Pharmacol Sci 2019; 23(14): 6008-10.
[7]
Di Trana A, Carlier J, Berretta P, Zaami S, Ricci G. Consequences of COVID-19 lockdown on the misuse and marketing of addictive substances and new psychoactive substances. Front Psychiatry 2020; 23; 11: 584462.
[8]
Malaca S, Busardò FP, Nittari G, Sirignano A, Ricci G. Fourth generation of synthetic cannabinoid receptor agonists: A review on the latest insights. Curr Pharm Des 2022; 28(32): 2603-17.
[9]
Gerace E, Seganti F, Di Corcia D, Vincenti M, Salomone A. GC-MS identification and quantification of the synthetic cannabinoid MDMB-4en-PINACA in cannabis-derived material seized in the turin metropolitan area (Italy). Curr Pharm Des 2022; 28(32): 2618-38.
[10]
Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, Schifano F. Designer benzodiazepines’ activity on OPIOID Receptors: A docking study. Curr Pharm Des 2022; 28(32): 2639-52.
[11]
Rossi B, Freni F, Carelli C, et al. Determination of traditional and designer benzodiazepines in urine through LC-MS/MS. Curr Pharm Des 2022; 28(32): 2622-38.
[12]
Concheiro M, Towler S, Elmore JS, et al. Brain concentrations of MDPV and its metabolites in male rats: relationship to pharmacodynamic effects. Curr Pharm Des 2022; 28(32): 2653-63.

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy